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Available online xxxxBackground:Myocardial infarction ismore likely if the heart damage biomarker cardiac troponin T (cTnT) is
elevated in a blood sample, indicating that cardiac damage has occurred. No method allows the clinician to esti-
mate the risk of myocardial infarction at a speciﬁc cTnT level in a given patient.
Methods: Predictive value among lookalikes (PAL) uses pre-test prevalence, sensitivity and speciﬁcity at adja-
cent cTnT limits based on percentiles. PAL is the pre-test prevalence-adjusted probability of disease between two
adjacent cTnT limits. If a chest pain patient's cTnT level is between these limits, the risk of myocardial infarction
can be estimated.
Results: The PAL based on percentiles had an acceptable sampling errorwhenusing 100 bootstrapped data of
18 different biomarkers from 38,945 authentic lab measurements. A PAL analysis of an emergency room cohort
(n= 11,020) revealed that the diagnostic precision of a high-sensitive cTnT assay was similar among chest pain
patients at different ages. The higher incidence of false positive results due to non-speciﬁc increases in cTnT in the
high-age group was counterbalanced by a higher pre-test prevalence of myocardial infarction among older pa-
tients, a ﬁnding that was missed when using a conventional ROC plot analysis.
Conclusions: The PAL was able to calculate the risk of myocardial infarction at speciﬁc cTnT levels and could
complement decision limits.
© 2016 The Authors. Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The clinical utility of a biomarker is often evaluated using binary
classiﬁcation that results in a fraction of patients with or without the
disease below or above a given biomarker level [1–6]. Some examples
are sensitivity (Sn) and speciﬁcity (Sp), where patients with or without
disease are analyzed separately (Fig. 1A), and negative and positive pre-
dictive values (NPV and PPV), where patients with and without disease
are analyzed together (Fig. 1A and Supplemental Tables 1 and 2).
An emergency roomphysician assessing the result of the heart dam-
age biomarker cardiac troponin T (cTnT) in a patient with chest pain is
often occupied with the following two questions:
1. If I exclude using the cTnT level in my patient, what fraction of pa-
tients with myocardial infarction (MI) will I miss?
2. At the patient level of cTnT, what is the probability of MI?alia, Institution of Biochemistry,
Medicine, Bruna Stråket 16,
-41345 Gothenburg, Sweden.
ammarsten).
. on behalf of The Canadian Society o
t al., Risk of myocardial infarc
), http://dx.doi.org/10.1016/j.cThe answer to the ﬁrst question is simply 1-Sn at the patient's cTnT
level; that is, the fraction of patientswithMI presentingwith cTnT levels
below the actual patient's level.
The probability of disease at a given cTnT level is more complicated.
The MI prevalence at a speciﬁc cTnT level increases along with the pre-
test MI prevalence, and is increased by age, smoking habits, male sex
and so forth [7]. Therefore, to answer how likely it is that this particular
patient has an MI, the calculations must also involve an estimate of the
patient's pre-test prevalence of MI.
Unfortunately, most binary classiﬁcations do not adjust for the pre-
test prevalence of disease. In addition, binary classiﬁcation results in a
fraction with disease above or below a given biomarker level, not the
probability of disease at the patient's biomarker level (Fig. 1B).
There are ways to use binary classiﬁcation in a pre-test prevalence-
sensitive manner, such as the likelihood ratio combined with Bayesian
reasoning [8] and prevalence-adjusted predictive values [9,10].
However, like all binary classiﬁcation, these calculationsuse the frac-
tion of patients above or below a given biomarker level and hence fail to
estimate the prevalence of disease at a speciﬁc biomarker level (Fig. 1B).
Slopes calculated from an ROC plot is one way to do this [11,12]. How-
ever, this method has not been extensively used.f Clinical Chemists. This is an open access article under the CC BY-NC-ND license (http://
tion at speciﬁc troponin T levels using the parameter predictive value
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Fig. 1.A.Visual demonstration of calculation of the speciﬁcity (Sp), the sensitivity (Sn), the
negative predictive value (NPV), and the positive predictive value (PPV). Frequency plots
of simulated data from individuals without (green line) and with (red line) disease. The
black vertical line indicates the biomarker action limit (see also Supplemental Tables 1
and 2). B. Frequency plots of simulated patient populations without (green line) or with
(red line) disease at a 50% and 10% disease prevalence. Numbers indicate the disease
prevalence above or at the biomarker level indicated by black vertical lines. C. Visual
representation of calculation of the predictive value among lookalikes (PAL). Frequency
plots of simulated patient populations without (green line) or with (red line) disease at
a 50% or 10% disease prevalence. The pairs of vertical lines represent the low and high
biomarker level used to calculate the PAL (see text and Supplemental Fig. 1 for details).
The PAL is the disease prevalence (numbers) in the shaded area between the two
biomarker levels. D. Visual representation of the sampling error of the PAL in relation to
the PPV from 20 normally distributed simulated patient data without (green dots) or
with (red dots) disease at a 50% disease prevalence. The numbers are the PAL calculated
from data between the two biomarker levels and the PPV calculated from data above
the action limit, indicated by black vertical lines. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
2 O. Hammarsten et al. / Clinical Biochemistry xxx (2016) xxx–xxxAt present, common methods using binary classiﬁcation are unable
to calculate the answer to the clinician's second question: “What is the
risk of MI at my patient's level of cTnT?”.
Here, we describe a parameter that makes it possible to calculate the
probability of disease at a speciﬁc biomarker level, predictive value among
lookalikes (PAL). The PAL is calculated using the pre-test prevalence in
combination with Sn and Sp between two adjacent biomarker levels.
The PAL can be used to generate pre-test prevalence-sensitive PAL plots
that visualize the interplay between the probability of disease and the
risk of missing a patient with the disease at speciﬁc biomarker levels.
2. Materials and methods
2.1. Simulations
Simulations were done in Excel 2011 for Mac OS 2011. Biomarker
data from healthy individuals were retrieved from the Nordic ReferencePlease cite this article as: O. Hammarsten, et al., Risk of myocardial infarc
among lookalikes (PAL), Clin Biochem (2016), http://dx.doi.org/10.1016/j.Interval Project 2000 (NORIP) database [13] (n ranging from 952 to
2740 for the 18 biomarkers analyzed). Diseased populations were sim-
ulated by scaling, where a ﬁxed factor was added to each lab data from
the NORIP database. These simulated disease data were used to assess
the sampling error of PAL.
The sampling error is the variation in PAL when PAL is repeatedly
calculated, typically 1000 times, from randomly selected subgroups of
data. If the data in the subgroups are randomly selected with replace-
ments called bootstrapping, each randomly selected subgroup of data
will essentially be unique.
In these calculations, data with or without the added factor were
randomly sampled with replacements. In each bootstrap, 100 authentic
lab data from the NORIP database from individuals without disease and
100 lab data with the added factor (i.e., the simulated diseased popula-
tion) were randomly selected.
From the bootstrapped data the Sn and the Sp were calculated at 21
biomarker limits derived from percentiles from the bootstrapped data
(Supplemental Fig. 1).
The Sn and the Spwere either the fraction of data above or below the
21 percentiles (non-parametric PAL calculation) or the integrated area
under the normal distribution at the 21 percentiles using the mean
and standard deviation (SD) from log-transformed data (parametric
PAL calculation, Supplemental Fig. 1).
The Sn and the Sp were used to calculate the PAL at 20 regions; conse-
quently, each PAL calculation included 5% of the combined bootstrapped
data from healthy and simulated diseased populations. The mean and the
2.5th and the 97.5th percentiles of the Sn, Sp and PAL from1000 bootstraps
were plotted to examine the general trend and the sampling error of the
different methods to calculate the Sn, Sp and PAL.
2.2. Analysis of PAL of high-sensitive cardiac troponin T
The study cohort comprised 11,020 visits to the emergency depart-
ment (ED) at Mölndal or Östra Hospital at the Sahlgrenska University
Hospital in Göteborg, Sweden, with a chief complaint of chest pain be-
tween January 2010 andDecember 2013. A characterization of admitted
patients with chest pain at these EDs from another time period has been
published before [14,15]. Only males with creatinine levels below
100 μmol/L were included, as kidney function strongly affects cardiac
troponin levels [16]. This resulted in the exclusion of 601 patients who
lacked a creatinine measurement in the laboratory database. Until the
end of January 2012, the hs-cTnT cutoff point for myocardial infarction
(MI) was 40 ng/L. In February 2012, the hs-cTnT cutoff point for MI
was changed to 14 ng/L. No point-of-care troponin assaywas in use dur-
ing the study and all troponin evaluations were made using the high-
sensitive cardiac troponin T assay (hs-cTnT) (Roche), analyzed by the
central lab. The local performance of the hs-cTnT assay has been report-
ed [17]. Only the ﬁrst hs-cTnT analysis result recorded during each ED
visit was used in Figs. 4 and 5. The ﬁnal diagnosis of each ED visit was
retrieved from the hospital registry. Laboratory data were retrieved
from the local laboratory database. The study was approved by the
Ethics Committee at the University of Gothenburg. The calculations of
parametric and non-parametric Sn, Sp and PAL were made using Excel
2011 for Mac OS 2011, as described in the text on log-transformed hs-
cTnT data. hs-cTnT limits were derived from 16 percentiles across the
MI cohorts.
3. Results and discussion
If the pre-test prevalence of disease is 50%, then the PPV, the proba-
bility of disease above a given biomarker level, can be calculated from
the Sn and Sp.
PPV ¼ Sn
Snþ 1−Spð Þ ð1Þtion at speciﬁc troponin T levels using the parameter predictive value
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3O. Hammarsten et al. / Clinical Biochemistry xxx (2016) xxx–xxxIf the odds of not having the disease are included in this equation, a
prevalence-adjusted PPV (PAP(+)) can be calculated at any disease
prevalence [9,10]:
PAP þð Þ ¼ Sn
Snþ β 1−Spð Þ ð2Þ
where β is is the ratio of patients with the disease to those without the
disease.
β ¼ nno disease
ndisease
ð3Þ
The same principle can be used to calculate the disease prevalence
between two biomarker levels, the predictive value among lookalikes
(PAL) (Fig. 1C, Supplemental Fig. 1):
PAL ¼ SnLow−SnHigh
SnLow−SnHigh
 þ β SpHigh−SpLow 
ð4Þ
where SnLow and SnHigh are the sensitivity and, SpLow and SpHigh are the
speciﬁcity at the adjacent lower and upper biomarker limits, respectively.
If the range between the upper and the lower biomarker level in-
cludes the biomarker level found in a patient, the probability of disease
can be estimated in a pre-test-sensitive way.
However, calculation of the PAL only involves study data between
the upper and lower biomarker limits. For that reason, the PAL sampling
error (see Materials and methods) may become unacceptably large if
the number of study data or the distance between the two adjacent bio-
marker levels is small (Fig. 1D).Fig. 2. Examples of PAL analysis of biomarker data. Frequency plots of creatinine (A, n =
2636) or bilirubin (B, n = 2740) levels in healthy individuals (green line) and simulated
data on diseased individuals (red line) at a 50% or 10% disease prevalence. The mean
PAL from 1000 bootstraps of 100 lab data from the green and red population is plotted
(magenta line). The non-parametric 95% conﬁdence limits from 1000 bootstraps are
shown with thin black lines. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
Please cite this article as: O. Hammarsten, et al., Risk of myocardial infarc
among lookalikes (PAL), Clin Biochem (2016), http://dx.doi.org/10.1016/j.cWe ﬁnd, however, that the overall trend of how the PAL changes
with biomarker levels is stable with an acceptable sampling error if
the biomarker limits for the PAL are derived from percentiles. We
have tested this using 21 limits across bootstrapped data sets of 100
lab data without disease and 100 simulated lab data with disease, so
that the 20 PAL calculations involve at least 5% of the data (Fig. 2).
This was done in order to avoid erratic sampling errors [18], if the Sp
or the Sn is close to zero at the low or high end of the data sets.
The 95% conﬁdence limits of the PAL growwider as the data from in-
dividuals without disease are ampliﬁed with the β factor in the PAL
equation (Fig. 2). This is particularly evident if the data have a log-
normal distribution like bilirubin (Fig. 2B).
It is possible to plot the 1-Sn against the PAL (Fig. 3). The resulting
PAL plot behaves like a ROC plot. The advantage, compared with the
ROC plot, is that the data on the longitudinal axis are affected by pre-
test prevalence and that the data on the horizontal axis describe the
risk of missing the disease (1-Sn). Therefore, the area under the PAL
plot (AUC) is dependent both on the pre-test prevalence and the bio-
markers' ability to separate patients with and without disease (Fig. 3)
In this setting, a biomarker that fails to separate individuals with or
without disease generates a PAL plot with a horizontal line at the dis-
ease prevalence. The horizontal line gives an AUC of 0.5 at a 50% disease
prevalence (Fig. 3A) and an AUC of 0.1 at a 10% disease prevalence
(Fig. 3B). A perfect separation of individuals with or without disease
generates an AUC close to 1 at any disease prevalence. Unlike ROCFig. 3. Comparison of a PAL plot and ROC plot analysis. Frequency plots of creatinine (n=
2636) levels from a healthy population (green lines) and a simulated diseased population
(red lines) at a 50% (A) and a 10% (B) disease prevalence. The separation between the
green and red population was made to generate an area under the ROC curve (AUC) of
0.5, 0.95 and 0.99. The magenta PAL (upper) and ROC plots (lower) are means from
1000 bootstraps of 100 lab data from the green and the red populations. The non-
parametric 95% conﬁdence limits from 1000 bootstraps are shown with thin black lines.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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disease prevalence and the risk of missing the disease at speciﬁc bio-
marker levels.
To be able to calculate the PAL at the patient's speciﬁc biomarker
level, we propose to use parametric Sp and Sn. The Sp and the Sn are
proportions that can be estimated from the cumulative area under the
normal distribution function.
Sp ¼ 1
SDh
ﬃﬃﬃﬃﬃﬃ
2π
p
 !
∫x
0
e
− x−Mno diseaseð Þ2
2SDno disease
2 dx ð5Þ
Sn ¼ 1− 1
SDd
ﬃﬃﬃﬃﬃﬃ
2π
p
 !
∫x
0
e
− x−Mdiseaseð Þ2
2SDdisease
2 dx ð6Þ
where x is the biomarker level, SDno disease and SDdisease is the standard
deviation, and Mno disease and Mdisease is the mean from the study data
for individuals with or without the disease (Supplemental Fig. 1).
As biomarkers oftendisplaynon-Gaussiandistribution, the paramet-
ric estimates of the Sp and the Sp are often better when using log-
transformed data (Fig. 4). With the parametric approach using log-
transformed data, the goodness of ﬁt with the non-parametric PAL
and sampling error (see Materials and methods) are often acceptable
when theparametric PAL is calculated from100 authentic labdatawith-
out disease and 100 simulated lab data with disease (Supplemental
Figs. 2–4). However, for some biomarkers, like creatine kinase, AST
and bilirubin, the parametric PAL is unable to generate an acceptable
ﬁt (Supplemental Figs. 2–4), as these biomarkers do not follow a normal
or log-normal distribution when analyzed with Q-Q plot and P-P plot
(data not shown).
In addition, the sampling error of a parametric PAL increases to a
larger extent compared with a non-parametric PAL when the data
from individuals without disease are ampliﬁed by the β factorFig. 4. Comparison of parametric and non-parametric PALs. Male patients with chest pain
(n=11,020) in the emergency department were analyzedwith a high-sensitive troponin
T analysis (hs-cTnT) at presentation. (A) Frequency plots of hs-cTnT levels in patientswith
(red lines) or without (green lines) myocardial infarction (MI). No MI = 10,369, MI =
608, MI frequency = 5.5%. Parametric (black lines) and non-parametric (magenta lines)
calculations of speciﬁcity, sensitivity (B), ROC plot (C) and PAL plots (D, E) at 16 hs-cTnT
percentiles across the MI cohort. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
Please cite this article as: O. Hammarsten, et al., Risk of myocardial infarc
among lookalikes (PAL), Clin Biochem (2016), http://dx.doi.org/10.1016/j.(Supplemental Figs. 2–4). However, if the Sp and the Sn are deﬁned
in a mathematical equation, the PAL can be calculated at patient-
speciﬁc biomarker levels.
The pre-test prevalence is a missing factor. Sometimes, the pre-test
prevalence is known. For instance, the pre-test prevalence of MI is
often 5%, if a patient presents with chest pain at an emergency depart-
ment in Sweden [14]. It is, however, important to note that the pre-
test prevalence depends on the clinical setting. It is likely that the
chance of MI being present given a set of symptoms will be different
in an emergency department with an efﬁcient triage process than in a
primary care setting.
The pre-test prevalence is often estimated using different score
systems, like Well's score for deep venous thrombosis [19]. However,
score systems use clinical ﬁndings and binary classiﬁcation to calculate
the probability of disease. Score systems are therefore also affected by
the pre-test prevalence. Hence, at a given Well's score, the risk of deep
venous thrombosiswill be different, ifWells score is applied in an emer-
gency department with an efﬁcient triage or in a primary care setting.
This possibly contributes to the variation in deep venous thrombosis
prevalence of 0–38% at a moderate Well's score in validation studies
[20].
A promising possibility is to use local hospital statistics to identify
stable baseline parameters, like chief complaint, age and gender,
which distinguish between patients with different pre-test disease
prevalences. Local hospital statistics and laboratory data can be used
to calculate the PAL for a biomarker in these risk categories, as we
have done for myocardial infarction (MI) and the myocardial infarction
biomarker, high-sensitive cardiac troponin T (hs-cTnT) (Figs. 4 and 5).Fig. 5. PAL analysis of the cardiac damage biomarker high-sensitive cardiac troponin T (hs-
cTnT) in different age groups. Male patients with chest pain in the emergency department
were analyzed with a high-sensitive troponin T analysis (hs-cTnT) at presentation.
Frequency plots of hs-cTnT levels in patients with (red lines) or without (green lines)
MI in the age range b60 years (No MI = 5723, MI = 153, MI frequency = 2.6%)
and N80 years (No MI = 1070, MI = 146, MI frequency = 12%). Non-parametric
calculations of speciﬁcity, sensitivity (B), ROC plot (C) and PAL plots (D, E) at different
levels of hs-cTnT on patients b60 years (black line) or N80 years old (blue line). (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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5O. Hammarsten et al. / Clinical Biochemistry xxx (2016) xxx–xxxPAL plot analysis on this chest pain population shows that at a given
chance of missing MI (1-Sn), the probability of MI is not very different
among older and younger chest pain patients (Fig. 5). Apparently, the
lower Sp of the hs-cTnT test due to non-speciﬁc minor hs-cTnT eleva-
tions among older patients (Fig. 5B) [21] is balanced by a higher pre-
test prevalence of MI in older patients (Fig. 5E). According to the PAL
plot, the hs-cTnT test ability to distinguish chest pain patients with or
without MI was similar at different ages, a fact not visualized by the
ROC plot analysis (Fig. 5D).
It is, however, important to note that these PAL calculations were
made using non-parametric Sn and Sp, and can therefore not be applied
to individual patients. In addition, the PAL for hs-cTnT must be further
validated in a separate cohort prior to clinical use.
In summary, the PAL and PAL plots can visualize the interplay be-
tween “what fraction of patients with the disease will I miss if I exclude
using my patient's biomarker value?” and “what is the probability of
disease in my patient?” and thereby complement decision limits.
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